Table 4.

Clinical trials investigating Tofacitinib and other JAKi in treatment of COVID-19.

Clinical trial identifier	Status	Study design	No. of enrolled	Age(y)	Jaki	Treatment	Outcomes
NCT04415151	Terminated	Randomized, parallel assignment, interventional	24	18–99	Tofacitinib	Tofacitinib-10 mg bid followed by 5 mg bid for 0–14 days vs. Placebo	Disease severity
NCT04469114	Completed	Randomized, multicentered, double-blind, placebo controlled, interventional	289	18∼	Tofacitinib	Tofacitinib-10 mg vs. placebo	Death or respiratory failure at day 28
NCT04390061	Not yet recruiting	Randomized, multicentered, open-label, interventional	116	18–65	Tofacitinib	Tofacitinib (10 mg bid) vs. Hydroxychloroquine	Prevention of severe respiratory failure requiring mechanical ventilation
NCT04332042	Not yet recruiting	Prospective cohort study, single group assignment, open-label, interventional	50	18–65	Tofacitinib	Tofacitinib- 10 mg bid for 0–14 days.	Patients requiring the use of mechanical ventilation for PaO2/FIO2 greater than 150
ChiCTR2000030170	Completed	Interventional	16	50–100	Jacketinib	Routine standard therapy + Jacketinib	Severe novel coronavirus pneumonia group: TTCI [time window: 28 days]
NCT04404361	Terminated	Randomized, parallel assignment, interventional	200	18∼	Pacritinib	Pacritinib vs. Placebo	Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization
NCT04402866	Completed	Randomized, parallel assignment, interventional	235	18–80	TD-0903	TD-0903 (pan-JAKi) vs. placebo	Respiratory failure free days

COVID-19 = coronavirus disease 2019; PAO2 = pressure of oxygen; FIO2 = Fraction of inspiration; TTCI = time to clinical improvement; ECMO = extracorporeal membrane oxygenation.